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A gas chromatography-microchip atmospheric pressure photoionization-mass spectrometric (GC-
APPI-MS) method was developed and used for the analysis of three 2-quinolinone-derived
selective androgen receptor modulators (SARMs). SARMs were analyzed from spiked urine samples,
whichwere hydrolyzed and derivatizedwithN-methyl-N-(trimethylsilyl)trifluoroacetamide before
analysis. Trimethylsilyl derivatives of SARMs formed both radical cations (M•) and protonated
molecules ([M  H]) in photoionization. Better signal-to-noise ratios (S/N) were obtained in
MS/MS analysis using theM• ions as precursor ions than using the [MH] ions, and therefore
the M• ions were selected for the precursor ions in selected reaction monitoring (SRM) analysis.
Limits of detection (LODs) with the method ranged from 0.01 to 1 ng/mL, which correspond to
instrumental LODs of 0.2–20 pg. Limits of quantitation ranged from 0.03 to 3 ng/mL. The mass
spectrometric response to the analytes was linear (R 0.995) from the LOQ concentration level up
to 100 ng/mL concentration, and intra-day repeatabilities were 5%–9%. In addition to the
GC-APPI-MS study, the proof-of-principle of gas chromatography-microchip atmospheric pres-
sure chemical ionization-Orbitrap MS (GC-APCI-Orbitrap MS) was demonstrated. (J Am Soc
Mass Spectrom 2010, 21, 310–316) © 2010 American Society for Mass SpectrometryMiniaturization of analytical devices has gaineda lot of attention in recent years, and a multi-tude of papers concerning the topic has been
published [1–3]. In mass spectrometry, the majority of
the effort has been put to miniaturization of ion sources,
especially electrospray ionization (ESI) [4]. However,
other miniaturized ion sources, e.g., the heated nebu-
lizer microchip for atmospheric pressure chemical ion-
ization (APCI) [5] and atmospheric pressure photoion-
ization (APPI) [6], and the nebulizer microchip for
sonic spray ionization (SSI) [7], have been reported as
well. The heated nebulizer microchips can be used to
connect a capillary liquid chromatograph (cap LC) [8, 9]
or a gas chromatograph (GC) [9–11], with any mass
spectrometer with an atmospheric pressure ionization
(API) source, or as a heated sprayer in desorption
atmospheric pressure photoionization [12]. In addition,
the heated nebulizer microchips have been shown to be
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doi:10.1016/j.jasms.2009.10.019suitable for the analysis of steroids [8, 9], polyaromatic
hydrocarbons [9], and drugs of abuses [13, 14], as well
as for quantitation of polychlorinated biphenyls from
soil samples [11].
Selective androgen receptor modulators (SARMs)
are an emerging group of pharmaceutical compounds
[15–17], which can be used in treatment of various
diseases, such as osteoporosis, cachexia related to can-
cer, and HIV wasting [18–20]. Contrary to anabolic
steroids, these compounds are tissue selective—the
desired anabolic effects in muscles and bones are sep-
arate from the undesired androgenic effects—which
make them attractive for treatment of diseases as well
as testing for illegal purposes such as doping in sports.
Analysis of SARMs in doping testing has an increasing
importance since the number of drug candidates with
anabolic effects is continuously growing [21]. SARMs
based on the structures of for example aryl propi-
onamide [22, 23], quinoline [24], 2-quinolinone [25], and
hydantoin [26] have been reported, and analytical
methods for 2-quinolinone-derived SARMs by liquid
chromatography-electrospray ionization-mass spectrome-
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impact ionization-mass spectrometry (GC-EI-MS) [28]
have been published. In this study, three nonsteroidal andro-
gen receptor modulators derived from 2-quinolinone, in-
cluding the drug candidate LGD-2226 [25, 29, 30], were
analyzed in urine after enzymatic hydrolysis and deriva-
tization by the combination of gas chromatography and
microchip atmospheric pressure photoionization-tandem
mass spectrometry (GC-APPI-MS/MS). The high re-
solving power of GC and the high sensitivity provided
by APPI together with selected reaction monitoring
(SRM) analysis with a triple-quadrupole MS shows
potential in doping analysis as shown below. In addi-
tion, the possibility to couple the API microchip with
a high-resolving power Orbitrap MS, enabling high-
resolution MS analysis together with GC, is demon-
strated (GC-APCI-Orbitrap MS). While the advan-
tages of the heated nebulizer microchip for analytical
work, i.e., high sensitivity and an insignificant dead
volume, have been demonstrated in previous studies [9,
11], this study further shows the feasibility of the
heated nebulizer microchip in bioanalytical applica-
tions. In comparison with the matrices in the previ-
ous GC-APPI-MS and GC-APCI-MS applications,
the biological sample matrix of the present study is
more challenging.
Experimental
Chemicals
Water was purified with a Milli-Q water purify-
ing system (Millipore, Molsheim, France). Methanol
and acetic acid were purchased from Mallinckrodt
Baker B.V. (Deventer, The Netherlands), N-methyl-
N-(trimethylsilyl)trifluoroacetamide (MSTFA), type HP-2
-glucuronidase, ethyl acetate, sodium acetate, and
toluene were from Sigma-Aldrich (Buchs, Switzer-
land and Steinheim, Germany). Oasis HLB solid-phase
extraction (SPE) cartridges, 3 cc, were purchased from
Waters (Milford, MA, USA). 2-Quinolinone derived
SARMs (6-bistrifluoroethylamino-, 6-bisethylamino-,
6-n-propyl-4-trifluoromethylquinolin-2(1H)-ones) (Struc-
tures 1, 2, and 3, respectively) were synthesized at the
Center for Preventive Doping Research (Institute of
Biochemistry, German Sports University, Cologne,
Germany) [30].Structure 1Sample Preparation
One mL of urine was spiked with the three SARM
compounds dissolved in ethyl acetate (10 L). pH was
adjusted to 5 by adding 0.75 mL of aqueous buffer (0.2
M sodium acetate, pH adjusted with acetic acid to 5),
and 20 L of -glucuronidase was added to the sample.
The solution was incubated at 50 °C for 60 min, and the
SARMs were extracted with SPE. Before the extraction,
the SPE cartridge was conditioned with 1 mL of meth-
anol and 1 mL of water. After introduction of the
sample solution (1.78 mL), the adsorbent was first
washed with 1 mL of water/methanol (90/10, vol/vol),
and the analytes were eluted with 1 mL of methanol.
The extract was evaporated to dryness under nitrogen
atmosphere at 60 °C. A total of 50 L of MSTFA was
added to the dried extract, which was then kept at 60 °C
for 10 min to derivatize the analytes. The MSTFA
solution was injected to GC as such. The same sample
preparation procedure was repeated to the samples
with varying SARM concentrations from 10 pg/mL to
100 ng/mL. In addition, six urine samples were pre-
pared to determine recovery; three samples were
spiked at the concentration level of 3 ng/mL before
extraction, while the other three samples were first
extracted and then spiked before the evaporation step.
For the optimization of the instrumental parameters, 10
L of stock solutions (1 mg/mL) of SARMs were
evaporated to dryness, and subsequently derivatized
with MSTFA similarly to the urine samples. The sam-
ples were diluted with MSTFA to obtain a working
solution of 10 g/mL (according to nonderivatized
compounds).
Fabrication of the Microchip
The heated nebulizer microchip consisted of silicon and
Pyrex glass wafers, which were bonded together by an-
odic bonding. The microchip featured an insertion chan-
nel for the sample capillary, an inlet for the auxiliary gas,
a vaporizer channel, and an exit nozzle. The height of the
vaporizer channel was 250 m and the width 800 m. A
detailed fabrication process of the microchip has been
Structure 2Structure 3
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lary (150 m i.d., 220 m o.d.) for sample introduction
was attached to the microchip with high temperature-
resistant epoxy glue (Duralco 4703; Cotronics Corp.,
Brooklyn, NY, USA).
Gas Chromatography and Connection to Mass
Spectrometry
An HP 5890 II gas chromatograph (Hewlett-Packard,
Waldbronn, Germany) was used for chromatographic
separation of the compounds. The GC was equipped
with a CTC-A200S autosampler (CTC Analytics, Zwin-
gen, Switzerland). A methyl deactivated retention gap
(length 1 m, i.d. 0.25 mm) was placed before the
analytical BPX5 column (length 15 m, i.d. 0.25 mm, 5%
phenyl 95% dimethylpolysiloxane, film thickness 0.25
m) (SGE Europe Ltd., Milton Keynes, UK). Injections
were done in the splitless mode, the injection volume
was 1 L, and the splitless time was 1 min. The carrier
gas (helium, 99.996%; AGA, Espoo, Finland) flow was
kept constant at 1.5 mL/min. The oven temperature
was held at 100 °C for 1 min, and raised to 280 °C at
20 °C/min. The injector was set to 300 °C. The platinum
heater on the microchip was heated using a laboratory
power supply with 2.0 W power, corresponding to a
temperature of approximately 250 °C. A heated transfer
line attached the GC system to the microchip. The
transfer line consisted of an original GC-MS transfer
line and of an additional resistance wire heater, which
were set to 300 °C and 280 °C, respectively. The capil-
lary column was drawn through the transfer line, and in
the coiled resistance wire heater part a deactivated glass
press-fit connector attached the GC column and the
silica capillary of the microchip. The auxiliary gas line
was attached to the microchip by pressing a Nanoport
fluidic connector (Upchurch Scientific Inc., Oak Harbor,
WA, USA) against the gas inlet with a custom-made
Table 1. Monitored SRM ion pairs from M• and [M  H] pr
ion pair for M• ions is shown in bold. Collision energies, detect
repeatabilities, and extraction recoveries are for M• ions
Three diagnostic
ion pairs and
quantitative
ion pair from
M● (m/z)
Three diagnostic
ion pairs from
[M  H] (m/z)
Co
en
Compound A-TMS 464/449 465/449
464/395 465/297
464/297 465/73
Compound B-TMS 356/341 357/341
356/313 357/311
356/297 357/297
Compound C-TMS 342/313 343/327
342/270 343/285
342/241 343/257
aFor M● ions.
bAverages of three concentration levels of SARMs in urine (three rep
B-TMS: 3, 10, and 30 ng/mL; Compound C-TMS: 1, 3, and 30 ng/mL.
cAverage of three replicates. SARM concentrations: 3 ng/mL in urine.holder. Auxiliary gas flow (nitrogen generated by What-
man 75-72 nitrogen generator; Whatman Inc., Haverhill,
MA, USA) was controlled by a mass flow controller and
set to 100 mL/min. In the GC-APCI-Orbitrap MS study,
the gas chromatographic part was similar to the one
described above for the triple-quadrupole MS study, ex-
cept that manual injection was used instead of the au-
tosampler. Experimental part for the GC-EI-MS study is
described elsewhere [28].
Mass Spectrometry
For GC-APPI-MS the conventional ion source of the
API3000 triple-quadrupole MS (Applied Biosystems/
MDS Technologies, Concord, Canada) was replaced by
a Nanospray stand (Proxeon Biosystems A/S, Odense,
Denmark) to enable the positioning of the microchip in
front of the MS orifice. Ionizing photons with 10 eV
energy and a minor proportion with 10.6 eV energy
were generated by a krypton discharge UV lamp
(Heraeus Noblelight, Cambridge, UK). Toluene was
pumped to the auxiliary gas line with a 3 L/min flow
rate, mixed with the auxiliary gas flow, and vaporized
to act as a dopant in photoionization. The MS/MS
collision energies were optimized by running GC iso-
thermally and injecting repeated split injections of stan-
dard solutions. Temperatures for isothermal runs were
250 °C, 280 °C, and 300 °C for Compounds A, B, and C,
respectively. Retention times of the analytes were de-
termined, and the MS spectra were recorded in the
positive ion full scan mode, using mass range of m/z
200–500. Finally, the SARMs were analyzed in positive
ion mode using SRM with 255 ms cycle time. The
collision energies are listed in Table 1. Three SRM ion
pairs per compound were monitored for qualification,
one of which was also used for quantification (Table 1).
Acquisition was divided to three periods according to
the retention times of the three SARMs.
or ions of trimethylsilyl derivatized SARMs. The quantitative
mits (S/N  3), quantitation limits (S/N  10), intra-day
n
a
Detection limit;
Quantitation
limit (ng/mL
in urine)
Peak area
repeatability
(RSD%)b
Retention
time
repeatability
(RSD%)b
Recovery
in SPE
(%)c
0.01; 0.03 7 0.03 92  3
1; 3 5 0.04 102  6
0.1; 0.3 9 0.05 111  2
s at each level): Compound A-TMS: 0.1, 3, and 30 ng/mL; Compoundecurs
ion li
llisio
ergy
(eV)
40
40
70
30
40
57
30
55
55
licate
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high-resolution MS was conducted by an Orbitrap MS
instrument (LTQ Orbitrap; Thermo Fischer Scientific,
Bremen, Germany). The microchip was placed in front
of the MS orifice similar to the GC-APPI-MS setup
described above. Corona discharge was used for ioniza-
tion. The instrument was operated in positive ion full
scan mode. Mass resolution value was set at 15,000, and
the mass spectra were recorded with 150 ms cycle time
using a mass range of m/z 70–500. The linear ion trap
was operated with helium (purity grade 5.0), and
nitrogen (from a nitrogen generator, CMC Instruments,
Eschborn, Germany) was used in the C-trap.
Results and Discussion
Chromatography
The GC temperature program was optimized for fast
and efficient separation. Full scan chromatograms and
mass spectra were acquired to determine the retention
times of the analytes. The analytes were completely
separated from each other. Based on the MS/MS frag-
mentation experiments (see the Discussion section be-
low), GC-APPI-MS/MS analysis was performed in
SRM mode with three SRM ion pairs (Table 1). Figure
1a shows the SRM chromatograms of the analytes,
obtained by summing all the SRM ion pairs. The
retention times of analyte peaks were repeatable (RSDs
0.03%–0.05%, Table 1), and the shapes of the peaks
were narrow (peak width at half maximum typically
1.2 s), which indicate the proper function of chroma-
tography and a minimal dead volume in the microchip.
Ionization and Mass Spectra
Atmospheric pressure photoionization (APPI) and at-
mospheric pressure chemical ionization (APCI) are re-
lated ionization methods in respect to producing, often,
the same kind of ions. Both APPI and APCI were
tested as ionization devices in the present study to
determine their applicability and ionization efficiency
for trimethylsilylated SARMs. APPI produced both
radical cations (M•) and protonated molecules ([M 
H]) whereas APCI produced only protonated mole-
cules. The mass spectrometric responses for ionized
analytes with both APPI and APCI were approximately
at the same level. Fragmentation of the analytes was not
observed in the MS spectra. The ratio of M• and [M 
H] signal intensities in APPI was 3:2. M• ions are
produced by charge exchange between the ionized dopant
(toluene) and analyte molecules in APPI, whereas [M 
H] ions are produced in the proton transfer reactions
between the reactant ions and the analytes in both APPI
and APCI [32, 33].
Product ions of both M• and [M  H] precursor
ions were first studied by infusion experiments with
APPI-MS/MS. Based on these experiments, GC-
APPI-MS/MS analysis was performed in the SRMmode using either M• or [M  H] as precursor ions
(Table 1), both with three SRM ion pairs. The ion
pairs from M• ions showed better signal-to-noise ratios
(S/N) compared with those obtained for the ion pairs
from [M  H] ions, and thus APPI was selected to be
used as the ionization method, and M• ions as the
precursor ions. According to our knowledge, the APPI-
MS/MS spectra (Figure 2) of the studied compounds
have not been published before. Figure 2a, b, and c
show MS/MS spectra of trimethylsilyl derivatives of
Compounds A, B, and C, respectively. Presented spec-
tra are the averages of multiple MS/MS spectra ob-
tained with different collision energies in the range
20–65 eV. From the measured product ion spectra,
some peaks can be easily recognized (Figure 2). All the
MS/MS spectra show TMS product ions at m/z 73;
peaks originating from methyl radical losses at m/z 449
(Figure 2a), m/z 341 (Figure 2b), and m/z 327 (Figure 2c);
and molecular ion peaks at m/z 464 (Figure 2a), m/z 356
(Figure 2b), and m/z 342 (Figure 2c). Another common
fragmentation route is the possible loss of H2C 
Si(CH3)2 (72 u) from the silylated site of the analytes,
Figure 1. (a) SRM chromatograms with all SRM ion pairs from
M• ions of trimethylsilylated SARMs. The analyte concentration
was 10 ng/mL of nonderivatized compounds in urine. (b) SRM
chromatograms of a blank urine sample.forming the product ions at m/z 392, 284, and 270 for
314 LUOSUJA¨RVI ET AL. J Am Soc Mass Spectrom 2010, 21, 310–316Compounds A, B, and C, respectively. Since APPI and
electron impact ionization (EI) both produce M• ions,
Figure 2. MS/MS spectra of the M• ions of trimethylsilylated
compounds obtained from GC peaks with APPI. The spectra are
the average spectra with different collision energies in the range
20–65 eV. (a) Compound A-TMS (M• ion at m/z 464), (b)
Compound B-TMS (M• ion at m/z 356), and (c) Compound
C-TMS (M• ion at m/z 342).similar product ions can be expected in APPI-MS/MSand EI-MS spectra, and are in fact observed. Figure 3
shows the EI-MS spectra of all the analytes. Resem-
blance of the mass spectra is clearly seen when compar-
ing the APPI-MS/MS spectra in the Figure 2 to the
EI-MS spectra in the Figure 3. This feature may be
advantageous in analyte characterization since the
APPI-MS/MS spectra of M• ions can be matched
against the EI-MS spectral libraries.
Analytical Performance of GC-APPI-MS
The performance of the analytical method was evalu-
ated with spiked urine samples. Trimethylsilylated
compounds were detected with three diagnostic SRM
ion pairs per compound. The method was observed to
be selective by comparing the extracted ion chromato-
grams of the SRM ion pairs of a spiked urine sample
and a blank urine sample (Figure 1 and Supplementary
Data, which can be found in the electronic version of
this article). The limits of detection (LODs) and the
limits of quantitation (LOQs) were determined from
single SRM ion pairs (Table 1). LODs for SARMs in
urine were in the range of 0.01–1 ng/mL with S/N  3,
and LOQs in the range 0.03–3 ng/mL with S/N 10. In
a previous study with LC-ESI-MS, the LODs for non-
derivatized 2-quinolinone-derived SARMs in urine
were reported to be in the range of 0.01–0.2 ng/mL [27],
and in a study with GC-EI-MS, the LOD was 0.2 ng/mL
for trimethylsilylated Compound A [28]. The World
Anti-Doping Agency’s minimum required performance
limit for an anabolic agent is 2 or 10 ng/mL in urine,
depending on the compound [34]. Our method fulfills
the requirements, especially in the case of the most
potent [25, 30] and, therefore, the most interesting
Compound A, LGD-2226. There are probably two rea-
sons for the excellent sensitivity of the method for
Compound A: the compound is effectively ionized due
to its high fluorine content, and there are only few
background compounds originating from the urine
matrix, while measuring the characteristic SRM ion
pairs (Figure 1 b and Supplementary Data). The mass
spectrometric response of the analytes was found to be
linear (R  0.995, with 1/x weighting, 4–8 concentra-
tion levels in a regression) from the LOQ concentration
level up to 100 ng/mL concentration. The relative
standard deviation of the peak areas in the SRM
chromatograms was low (5%–9%) for all the com-
pounds (Table 1). In addition, the extraction recovery
percentages (92%–111%) are acceptable and have
only a little variation within three replicates (2%–6%)
of each compound. The method shows potential for
quantitative analysis due to these characteristics.
However, in doping analysis, qualitative analysis is
often sufficient.
Demonstration: GC-APCI-Orbitrap MS
The selectivity and thus the analytical performance of
the method can be further enhanced by using an MS
Compound C-TMS (M• ion at m/z 342).
315J Am Soc Mass Spectrom 2010, 21, 310–316 SARM ANALYSIS BY GC-APPI-MSwith a high resolving power. The combination of GC-
API with such an instrument, Orbitrap MS, was dem-
onstrated. APCI with corona discharge was used for the
ionization, and formation of [M  H] ions was clearly
observed. Therefore, the analytical results obtained
with this combination are not fully comparable with the
results obtained with GC-APPI-MS using the M•
ions, but replacing the corona discharge needle with a
UV lamp is possible if photoionization is favored.
Extracted ion chromatograms of the [MH] ions with
a very narrow m/z window (0.03 u) for trimethylsily-
lated SARMs from a GC-APCI-Orbitrap MS run are
presented as an example of the results (Figure 4),
demonstrating the decreased background interference
when accurate masses can be used for extraction of the
ion chromatograms. In addition, identification of the
analytes by comparing the measured accurate masses
with the calculated exact masses facilitates the analysis
of complex mixtures and enables a more selective and
specific analysis. An excellent agreement between the
measured and the calculated masses was observed
(mass error  2 ppm), since the measured masses of
Compounds A, B, and C were m/z 465.1048, 357.1611,
and 343.1453, whereas the calculated masses are m/z
465.1045, 357.1610, and 343.1453, respectively.
Conclusions
Potential doping compounds, 2-quinolinone derived
SARMs, were analyzed from urine samples. The novel
analytical method, GC-APPI-MS, showed low limits
of detection for the studied compounds, and feasibility
Figure 4. Extracted ion chromatograms (EIC) of the three trim-
ethylsilylated SARMs and a total ion chromatogram (TIC) from a
GC-APCI-Orbitrap MS run. (a) EIC at mass range m/z 465.09–
465.12, (b) EIC at mass range m/z 357.15–357.18, (c) EIC at mass
range m/z 343.13–343.16, and (d) TIC at mass range m/z 70–500.
Concentration of nonderivatized analytes is 10 g/mL.Figure 3. EI-MS spectra of the trimethylsilylated SARMs ob-
tained from a GC-EI-MS run. (a) Compound A-TMS (M• ion at
m/z 464), (b) Compound B-TMS (M• ion at m/z 356), and (c)of the heated nebulizer microchip for bioanalytical
316 LUOSUJA¨RVI ET AL. J Am Soc Mass Spectrom 2010, 21, 310–316applications was shown. The important advantage ob-
tained by heated nebulizer microchips is the possibility
to combine efficient separation with any mass spectrom-
eter equipped with an atmospheric pressure ionization
interface. The demonstrated possibility to combine the
heated nebulizer microchips with a high-resolution MS
instrument empowers even more efficient GC-API-MS
analysis. The characteristic feature of APPI, the produc-
tion of radical cations, may be beneficial in analyte char-
acterization since APPI-MS/MS spectra of radical cations
can be matched against the EI-MS spectral libraries.
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